Does CBD Improve Sleep Quality? What Does Scientific Research Say?

Does CBD improve sleep quality? Short answer: for some individuals with anxiety or stress-induced insomnia, cannabidiol may shorten the time to fall asleep, reduce the number of nighttime awakenings, and improve subjective feelings of restfulness, but clinical evidence is still limited. A meta-analysis of 34 randomized studies (Bhagavan et al., Journal of Clinical Medicine, 2020) indicated that standalone CBD in doses of 25-1500 mg daily has a weak to moderate effect on sleep parameters, and the effect depends on the population, dosage, form, and timing of administration. In this guide, I explain what the studies show, how CBD affects sleep architecture, why it cannot replace CBT-I, and how to safely experiment with dosing under a doctor's supervision.

Author: Michał Waluk. Educational article, not medical advice. Before starting to use CBD, consult with a doctor, especially in cases of chronic insomnia, depression, anxiety disorders, pregnancy, and when taking medications.

Do clinical studies confirm that CBD improves sleep?

The most frequently cited study by Shannon et al. (The Permanente Journal, 2019) on 72 adult psychiatric patients showed that after a month of using 25-175 mg CBD, Hamilton Anxiety Rating Scale scores decreased in 79.2% of participants, and subjective sleep quality improved in 66.7% of participants, although the effect on sleep was less stable than the anxiolytic effect.

What does the Shannon 2019 study show?

Shannon recruited 103 patients from an outpatient clinic; the final analysis included 72 individuals with complete documentation for at least three months. The dosing ranged from 25-175 mg of CBD daily, most commonly 25 mg in the morning or evening. The PSQI (Pittsburgh Sleep Quality Index) and Hamilton Anxiety Rating Scale were assessed monthly.

The results were asymmetrical: anxiety decreased steadily and was maintained over three months of observation. Sleep improved in two-thirds of patients in the first month, but fluctuated in subsequent months. The authors conclude that CBD may support sleep secondarily by suppressing anxiety-related nighttime arousal, rather than through a direct sedative effect.

However, the limitations are significant: this is an observational study, without a placebo group and randomization. Patients knew their therapy, which increases the risk of a placebo effect. As the authors themselves emphasize, the results require confirmation in double-blind studies.

Other randomized studies on CBD and sleep

Contrary to common marketing narratives, a large portion of randomized studies did not show a significant advantage of CBD over placebo. Carlini and Cunha (Journal of Clinical Pharmacology, 1981) on 15 patients with insomnia showed that 160 mg of CBD extended sleep by 60 minutes compared to placebo, but in the study by Linares et al. (Frontiers in Pharmacology, 2018) 300 mg of CBD did not differ from placebo in any polysomnographic parameter in healthy volunteers.

A meta-analysis by Kaul et al. (Current Psychiatry Reports, 2021) included 19 clinical studies on CBD and sleep. The conclusions are cautious: CBD may exhibit moderate effects in secondary insomnia due to anxiety, PTSD, or chronic pain, while in primary insomnia, the evidence is inconsistent, and sample sizes are too small.

In the study by Babson et al. (Current Psychiatry Reports, 2017) it was emphasized that most previous trials had fewer than 100 participants, lasted less than eight weeks, and rarely included objective polysomnographic measurements, which significantly weakens the strength of the evidence.

The best observational study on CBD and sleep (Shannon et al., The Permanente Journal, 2019, n=72) showed an improvement in sleep quality in 66.7% of patients after a month of therapy with 25-175 mg of CBD, but the effect was unstable in subsequent months, and without a placebo group, the psychological effect cannot be ruled out.

pillar article on the impact of cannabis on sleep

How does CBD affect sleep architecture (REM and NREM phases)?

CBD in doses of 15-160 mg does not significantly disrupt sleep architecture in healthy individuals, as confirmed in the polysomnographic study by Linares et al. (Frontiers in Pharmacology, 2018) conducted in Sao Paulo. Unlike THC, which suppresses REM sleep and can cause a rebound effect after withdrawal, CBD in moderate doses maintains the physiological cycle of sleep.

The difference between CBD and THC in sleep

THC, the main psychoactive component of cannabis, shortens sleep latency but significantly reduces REM sleep, where emotional and procedural memory is consolidated (Gates et al., Sleep Medicine Reviews, 2014). After discontinuation of THC, a REM rebound effect occurs: intense, often unpleasant dreams, sweating, withdrawal insomnia.

CBD does not produce such an effect. In the study by Chagas et al. (Journal of Clinical Pharmacy and Therapeutics, 2014) in patients with REM sleep behavior disorder (RBD) due to Parkinson's disease, 75-300 mg of CBD reduced the number of motor episodes without changing the duration of REM, which is clinically significant.

From a practical standpoint, this means that in broad-spectrum (THC-free) or isolate products, you maintain the quality of deep sleep and the restorative REM phase. Full-spectrum products containing trace amounts of THC (up to 0.3%) with chronic use in high doses may affect REM, although the evidence is limited.

Impact on deep sleep (NREM N3)

Deep sleep (N3 phase, slow-wave) is responsible for physical regeneration, memory consolidation, and brain cleansing through the glymphatic system (Xie et al., Science, 2013). A deficiency in N3 is associated with an increased risk of neurodegenerative diseases.

Observational studies on CBD and deep sleep are rare. The work of Murillo-Rodriguez et al. (Pharmacology Biochemistry and Behavior, 2014) in a rat model suggests that CBD prolongs slow-wave sleep by modulating the adenosine system. In humans, confirmation of this observation requires polysomnography, which was simply not performed in most trials.

How does CBD act on sleep-regulating receptors?

CBD does not bind directly to cannabinoid receptors CB1 and CB2 as strongly as THC. Instead, it acts as an allosteric modulator and influences many other systems, including 5-HT1A, GABA-A, PPAR-gamma, and vanilloid receptors TRPV1 (McPartland et al., British Journal of Pharmacology, 2015), which explains its diffuse, primarily anxiolytic effect.

The role of the endocannabinoid system

The endocannabinoid system (ECS) regulates the body's homeostasis, including the sleep-wake cycle, appetite, mood, and pain perception. The key endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). CBD inhibits the FAAH enzyme, which breaks down anandamide, thereby increasing the level of this endogenous "molecule of happiness" in the brain.

CB1 receptors in the hypothalamus and brainstem participate in regulating the circadian rhythm. Activation of CB1 by high levels of anandamide promotes sleep onset. This is an indirect mechanism through which CBD may support sleep without inducing psychoactivity.

Serotonin receptor 5-HT1A and anxiolytic effect

CBD is a full agonist of the 5-HT1A receptor, similar to buspirone, but with a different pharmacological profile. Russo et al. (Neurochemical Research, 2005) demonstrated that this binding is responsible for the anxiolytic effect of CBD, repeatedly confirmed in behavioral studies in animals and humans.

Since anxiety is a major factor in chronic insomnia (present in 40-60% of patients according to DSM-5-TR, 2022), reducing anxiety directly translates to better sleep. This explains why CBD seems to be more effective in individuals with anxiety-related insomnia than in primary insomnia.

GABA-A and the glutamatergic system

Studies by Bakas et al. (Pharmacological Research, 2017) indicate that CBD allosterically modulates the GABA-A receptor, enhancing the action of the main inhibitory neurotransmitter in the brain. The mechanism is much subtler than that of benzodiazepines (diazepam, lorazepam), which explains the absence of addiction and receptor tolerance in previous observations.

At the same time, CBD reduces excessive glutamatergic activation, which in practice means less "racing mind" before sleep. In our customer observations, this effect is described as a "quieter internal monologue" about 30-60 minutes after taking sublingual oil.

What CBD dosage for sleep is effective?

The effective dose of CBD for sleep is not established and varies in studies from 25 mg to 600 mg daily, with a surprising biphasic dose-response relationship. Zuardi et al. (Frontiers in Pharmacology, 2017) demonstrated in a social anxiety model that both 150 mg and 600 mg were less effective than 300 mg, suggesting an inverted U-curve in the dose-effect relationship.

Low activating doses vs high sedative doses

Based on Nicholson et al. (Journal of Clinical Psychopharmacology, 2004) and later meta-analyses, three ranges of CBD doses can be distinguished in the context of sleep:

• Microdoses (1-10 mg): clinical effect questionable, often placebo; in some subjective reports, stimulation is reported.
• Low doses (15-25 mg): mild anxiolysis, paradoxically activating in some individuals; can be used in the morning for patients with anxiety.
• Medium doses (50-150 mg): typical anxiolytic and sleep-supporting range; in Shannon 2019, the range of 25-175 mg proved effective for most.
• High doses (300-600 mg): clear sedation, used in studies on drug-resistant epilepsy (Devinsky, New England Journal of Medicine, 2017); potentially effective in severe insomnia, but costly and taxing on the liver.

Practical dosing schedule

A typical schedule used by clients reporting improved sleep: start with 15-25 mg of broad-spectrum oil 60-90 minutes before planned sleep, daily for 14 days. After two weeks, evaluate in a sleep diary (time to fall asleep, number of awakenings, subjective assessment of restfulness). No effect is a signal to increase by 10-15 mg every 7 days, up to a maximum of 100 mg.

Timing matters. In the Linares 2018 study, CBD taken 30 minutes before sleep produced different effects than taken in the morning. Sublingual oil acts faster (15-45 minutes to peak), capsules and gummies slower (45-120 minutes), which should be considered in the schedule. Taking with a fatty meal increases oral bioavailability by up to four times (Birnbaum et al., Epilepsy, 2019).

Expected time to first effects

Meta-analyses suggest that the effect on sleep usually appears after 1-4 weeks of regular use, rather than from the first dose. The initial "instinctive" improvement after the first intake is often a placebo effect or passive relaxation from an evening ritual. Keeping a sleep diary for at least 14 days before and 14 days after is the best assessment tool.

The CBD dose-response curve in sleep is non-monotonic: in the Zuardi 2017 study (Frontiers in Pharmacology) 300 mg proved more effective than 150 mg and 600 mg, which means that "more" does not always mean "better" and the principle of titrating from the lowest effective dose has strong pharmacological foundations.

detailed dosing guide

What forms of CBD work best for sleep?

Sublingual CBD oils and gummies with added melatonin are the two most commonly recommended forms for supporting sleep. A 2023 ConsumerLab market analysis found that 78% of CBD products dedicated to sleep are oils or gummies, while 22% are capsules or sprays. Differences in bioavailability and onset time are crucial for the timing of intake.

Sublingual CBD oil

Oil is the most studied form. Sublingual bioavailability is 13-19% (Millar et al., Frontiers in Pharmacology, 2018), and the time to peak concentration is 30-90 minutes. Holding the oil under the tongue for 60-90 seconds significantly increases absorption. Broad-spectrum oil contains CBD plus smaller cannabinoids (CBG, CBN, CBC) without THC.

Examples of broad-spectrum products include SOOL Broad Spectrum CBD 5% (500 mg CBD in 10 ml, about 2.5 mg/drop, 76 PLN) for those starting therapy and SOOL Broad Spectrum CBD 10% (1000 mg CBD in 10 ml, about 5 mg/drop, 99 PLN) for those requiring higher doses in smaller volumes.

CBD gummies with melatonin

Gummies (jellies) are a capsule form, absorbed mainly in the small intestine. Bioavailability is lower (6-15%), but the duration of action is longer (4-8 hours), which can be beneficial for nighttime awakenings. The combination of CBD with melatonin (1-5 mg) showed a synergistic effect in the study by Palmieri et al. (Medicines Basel, 2017) on 409 patients with chronic pain.

Melatonin itself is the best-documented circadian rhythm supplement. A meta-analysis by Ferracioli-Oda et al. (PLOS ONE, 2013) showed that it shortens sleep latency by an average of 7 minutes and extends total sleep time by 8 minutes. The combination with CBD may provide a complementary effect: melatonin targets the circadian rhythm, while CBD targets tension and anxiety.

Capsules and vaporized flower

Capsules offer precise dosing (usually 10-25 mg per piece) and no cannabis taste. Bioavailability is the lowest (6-12%), but predictability is the highest. For those counting milligrams, this is a convenient option.

Vaporizing flower or bud rich in CBG/CBD (like Mars CBD Hemp Herb 9% from Konopny Buch, 59 PLN) provides the fastest effect (bioavailability 31%, peak 5-10 minutes), but acts briefly (2-3 hours) and requires a responsible vaporizer, not smoking. Smoking flower produces tar and carcinogenic substances, so it is not recommended in the context of health.

CBG oils and other minor cannabinoids

CBG (cannabigerol) is a precursor to many cannabinoids and exhibits anxiolytic and neuroprotective effects, although there is less research on sleep than for CBD. Products such as Cannova CBG 15% (1500 mg CBG in 10 ml, 240 PLN) offer a high concentration of CBG, often in combination with CBD. Some users report better effects from combining CBG with CBD in a 1:1 ratio in their evening routine, although large clinical studies confirming synergy are lacking.

Does CBD help with sleep apnea and restless legs syndrome?

In sleep apnea (OSA) and restless legs syndrome (RLS), evidence for the effectiveness of CBD is preliminary and indirect, without randomized phase III trials. A pilot study by Prasad et al. (Frontiers in Psychiatry, 2013) on 8 patients with OSA showed that dronabinol (synthetic THC) reduced the AHI rate, but CBD itself was not tested. The American Academy of Sleep Medicine in 2018 explicitly does not recommend cannabinoids as treatment for OSA.

Sleep apnea (OSA)

Sleep apnea requires causal treatment: most commonly CPAP, weight reduction, upper airway surgery. CBD does not affect the mechanism of throat collapse, does not tighten the oropharyngeal muscles, and does not affect receptors regulating respiratory drive.

Moreover, in individuals with untreated OSA, the use of any sedatives, including high doses of CBD, may worsen sleep safety. The American Academy of Sleep Medicine (AASM) in its 2018 position and 2024 update clearly states: medical cannabinoids are not indicated in the treatment of sleep apnea, and CPAP remains the standard.

Restless legs syndrome (RLS)

In RLS, the evidence is marginally better. Case reports by Megelin and Ghorayeb (Sleep Medicine, 2017) indicate that 6 out of 6 patients with drug-resistant RLS reported relief after smoking marijuana, but this is very preliminary data. It is unclear whether the effect is due to CBD, THC, terpenes, or general sedation.

First-line treatment for RLS remains dopamine agonists (pramipexole, ropinirole), gabapentinoids (gabapentin, pregabalin), iron supplementation in case of deficiency. CBD may be considered as support, but not a substitute, under medical supervision and after excluding interactions with gabapentinoids.

How does CBD compare to sleeping pills?

CBD is generally safer than classic sleeping pills in terms of addiction, but weaker in directly inducing sleep. An AHRQ report (Agency for Healthcare Research and Quality, 2017) assessed that benzodiazepines and Z-drugs (zolpidem, eszopiclone) shorten sleep latency by 22-42 minutes, while for CBD, the average effect hovers around 10-15 minutes, with a significantly lower risk profile for physical addiction.

Zolpidem, eszopiclone, and other Z-drugs

Zolpidem and eszopiclone are effective (NNT about 13 for insomnia remission after 4 weeks), but have significant limitations: tolerance after a few weeks, risk of physical and psychological addiction, parasomnias (sleep eating, sleepwalking), increased risk of falls in seniors (Glass et al., BMJ, 2005). The FDA has required a "black box warning" on zolpidem since 2019 after reports of serious injuries in a semi-conscious state.

CBD does not exhibit addictive potential in the WHO classification (Expert Committee on Drug Dependence, 2018), does not cause parasomnias, and does not impair coordination to such an extent. This does not mean it is "harmless", but the safety profile is clearly more favorable.

Ramelteon and melatonin receptor agonists

Ramelteon (not registered in Poland, available in the USA) is a selective agonist of MT1/MT2 receptors and has a profile closest to "physiological" sleep. It mainly affects latency, less so on sleep maintenance. Compared to CBD, it has stronger evidence, a shorter time to effect, but a narrower indication (insomnia with difficulty falling asleep).

In Poland, melatonin is available OTC (1-5 mg) and prolonged-release prescription preparations. The combination of CBD with melatonin may be a reasonable strategy for individuals with mixed insomnia (difficulty falling asleep plus nighttime awakenings), but always after consultation with a doctor.

Benzodiazepines and their limitations

Benzodiazepines (diazepam, lorazepam, temazepam) are effective short-term, but their use beyond 2-4 weeks carries a high risk of addiction and cognitive impairment in seniors (Kripke, BMJ Open, 2012, indicated a 3.6-fold increased risk of mortality). Current guidelines from many scientific societies discourage benzodiazepines in chronic insomnia.

CBD in this context may be an alternative for individuals with mild to moderate insomnia who do not want to resort to high-risk medications. However, this is always a medical decision, not self-medication, especially in the presence of comorbid disorders.

Why CBT-I is the first-line treatment

The most underrated information in discussions about CBD and sleep: guidelines from the American College of Physicians (Qaseem et al., Annals of Internal Medicine, 2016) and AASM unequivocally recommend cognitive-behavioral therapy for insomnia (CBT-I) as first-line treatment for chronic insomnia in adults. CBT-I in meta-analyses shows effects equivalent to or better than sleeping pills, lasting after therapy ends, without adverse effects.

CBD, zolpidem, melatonin, and other agents are second-line options. Many people overlook CBT-I because it is less accessible than a pill or oil, but it is precisely this that yields the most lasting effects. CBD may be a reasonable complement to CBT-I in patients with an anxiety component, but it will not replace work on sleep hygiene, stimulus control, and cognitive restructuring.

What are the side effects and interactions of CBD?

CBD is well tolerated in 85-95% of users, but it is not without risk. A systematic review by Chesney et al. (Neuropsychopharmacology, 2020) on 12 studies with a total of 1200 patients reported the most common adverse effects: diarrhea (11%), drowsiness/sedation (7%), changes in appetite (6%), dizziness (4%), and transient elevation of liver enzymes (ALT, AST) in 5-20% at doses above 300 mg daily.

Typical side effects

The most common effects are: daytime sedation (especially with high evening doses), gastrointestinal disturbances (diarrhea, nausea), dry mouth, changes in appetite and body weight. Some effects subside after 2-4 weeks of adaptation or dose reduction.

Less common but significant: elevated liver enzymes. In studies on drug-resistant epilepsy (Devinsky, NEJM, 2017) ALT exceeded three times the upper limit of normal in about 15% of patients taking 20 mg/kg/day, which requires periodic monitoring of transaminases in individuals using high doses chronically.

Interactions with medications: CYP3A4 and CYP2D6

CBD inhibits cytochrome P450 CYP3A4 and CYP2D6, crucial for the metabolism of about 60% of prescription medications (Brown and Winterstein, Journal of Clinical Medicine, 2019). The most clinically significant interactions include:

• Warfarin: CBD increases INR, cases of bleeding have been reported; requires strict INR monitoring.
• Statins (simvastatin, atorvastatin): increased concentration, risk of myopathy.
• SSRIs (sertraline, escitalopram, fluoxetine): risk of increased concentration and serotoninergic side effects.
• Benzodiazepines (clonazepam, diazepam): potentiation of sedation.
• Anticonvulsants (clobazam, valproate): significant increase in the concentration of active metabolites.
• DOAC anticoagulants (rivaroxaban, apixaban): risk of increased concentration and bleeding.
• Proton pump inhibitors (omeprazole): mutual metabolic interactions.

Absolute and relative contraindications

Absolute contraindications: pregnancy and breastfeeding (lack of safety data, CBD passes into milk), severe liver failure (Child-Pugh C), allergy to cannabis or carrier ingredients (hemp oil, MCT).

Relative: children and adolescents without medical indications (drug-resistant Dravet/Lennox-Gastaut epilepsy with documented prescription), Parkinson's disease while using levodopa, severe depression with suicidal thoughts, psychotic disorders with active symptoms, planned surgery (discontinue 48 hours prior).

CBD and alcohol

Concurrent use of CBD with alcohol enhances sedation and impairs coordination. Although studies are limited (Belgrave et al., Journal of Clinical Pharmacology, 1979), it is not recommended to combine them, especially when driving or operating machinery.

CBD interacts with about 60% of drugs metabolized by CYP3A4 and CYP2D6 (Brown and Winterstein, Journal of Clinical Medicine, 2019), which includes warfarin, statins, SSRIs, benzodiazepines, and anticonvulsants. Anyone taking medications chronically should discuss introducing CBD with their doctor and monitor appropriate laboratory parameters.

Does tolerance to CBD develop with chronic use?

Unlike benzodiazepines and opioids, CBD has not shown the classical phenomenon of receptor tolerance in studies lasting up to 4 years (Gaston et al., Epilepsy, 2017). However, clinical observations of patients self-escalating doses suggest that in 15-20% of users, the subjective effect on sleep weakens after 6-12 weeks of regular use, which may result from behavioral tolerance or metabolic adaptation.

Receptor tolerance vs metabolic adaptation

Receptor tolerance is the phenomenon of decreased cellular response to the same stimulus, caused by receptor internalization. For CBD, there is no compelling evidence of such tolerance in the 5-HT1A system or ECS in humans.

However, metabolic adaptation (enzyme induction) is possible. At high doses, CBD can lead to autoinduction of metabolism, resulting in faster breakdown and lower concentrations in plasma. In practice, this manifests as "reduced effectiveness", which users interpret as tolerance.

Therapeutic breaks ("drug holidays")

A strategy we observe in long-term users: breaks 1-2 times a week (e.g., a weekend without CBD) or 1 week without CBD every 2-3 months. There is no strong clinical evidence supporting this practice, but subjectively it can be effective in maintaining the effect.

If the effect completely fades after a few months, it is worth returning to the doctor and considering another therapeutic strategy: a different form of CBD, adding CBG or CBN, CBT-I, psychiatric consultation for treating underlying insomnia or anxiety.

When to see a doctor instead of trying CBD?

CBD is not a substitute for diagnosis or treatment. Chronic insomnia, defined as difficulty sleeping at least 3 nights a week for 3 months, affects 10-15% of adult Poles (Nowicki et al., Psychiatry Poland, 2016) and requires medical evaluation. Five red flags indicate the need for urgent medical consultation instead of self-experimentation with CBD.

Red flags for insomnia

• Snoring with breathing pauses, observed by a partner or recorded by applications – suspicion of sleep apnea requires polysomnography.
• Excessive daytime sleepiness, falling asleep at the wheel – risk of accident, requires diagnostics at a sleep disorders clinic.
• Suicidal thoughts, deep depression, loss of interest – urgent psychiatric consultation, not CBD.
• Nightmares with trauma or flashbacks – suspicion of PTSD, requires specialized treatment.
• Insomnia + weight loss, night sweats, shortness of breath – exclude somatic diseases (hyperthyroidism, cancers, heart failure).

When CBD may be a reasonable supportive option

CBD can be considered as support, not first-line therapy, in the following situations after consulting with a doctor: mild to moderate insomnia with an anxiety component, support for CBT-I in patients with heightened anxiety, situational insomnia (stress, job change, grief) for up to 4-8 weeks, insomnia with chronic pain as a complement to pain treatment.

In each of these scenarios, CBD plays a secondary role. The first steps are always: assessing sleep hygiene, maintaining a regular circadian rhythm, limiting caffeine after 2 PM, physical activity (but not in the evening), exposure to daylight in the morning, and limiting screens in the evening.

Where to seek help in Poland

The Polish Sleep Research Society (PTBS) maintains a register of sleep disorder clinics. Specialized centers have polysomnography labs and offer CBT-I online or in-person. As a first line, you can consult a family doctor who will assess somatic risk and refer you to a psychiatrist, neurologist, or pulmonologist.

How to integrate CBD with sleep hygiene and evening routine?

CBD works better as part of a comprehensive strategy than as a standalone remedy. A meta-analysis by Irish et al. (Sleep Medicine Reviews, 2015) showed that behavioral interventions (regular schedule, bedroom temperature, stimulus control) reduce insomnia severity by 35-50% regardless of supplementation, and their effect is lasting. Adding CBD may provide an additional 5-15 percentage points of improvement in individuals with an anxiety component.

Evening protocol step by step

A sample protocol based on AASM recommendations and clinical observations:

1. 19:00-20:00: light dinner, caffeine and alcohol-free; last meal 2-3 hours before sleep.
2. 20:00-21:00: reduce blue light, filters on screens or blue-light blocking glasses; quieting mental activity.
3. 21:00-21:30: 15-30 mg of CBD sublingually, hold under the tongue for 60-90 seconds; alternatively, CBD gummies + melatonin (consider longer onset time).
4. 21:30-22:15: calming ritual: reading (paper), warm shower (36-38 degrees), stretching, meditation, 4-7-8 breathing.
5. 22:15-22:30: bedroom cool (18-19 degrees), dark, quiet; phone outside the bedroom or in night mode.
6. 7:00-7:30 AM: waking up at a consistent time, exposure to daylight for 10-15 minutes, physical activity or a walk.

Sleep diary: assessment tool

A sleep diary kept for at least 14 days before starting CBD and for 14 days during therapy objectively shows whether an effect exists. Record: time of going to bed, estimated time to fall asleep, number and time of awakenings, time of getting up, subjective assessment of sleep quality (1-10) and morning well-being (1-10), caffeine intake, physical activity, CBD dose.

After a month, you have hard data instead of "I think I'm sleeping better." If the improvement is less than 20% or absent, it's worth changing the strategy: a different dose, form, time, or a completely different therapeutic direction.

Is CBD legal and how to choose a safe product?

In Poland, CBD derived from hemp (Cannabis sativa L.) with a THC content below 0.3% is legal under the 2022 drug prevention law. A report from the Polish Institute of Hemp (PIK, 2023) estimated the Polish market for CBD products at about 180 million PLN annually, with a dynamic growth of 25-30% year on year, while the quality of products is highly variable and requires critical consumer evaluation.

Certificates and laboratory tests

A safe product should have: current HPLC analysis results (COA certificate), documentation of the absence of heavy metals (cadmium, lead, arsenic, mercury), tests for pesticides and residual solvents, correct labeling of CBD and THC content, address and details of the manufacturer.

The American FDA in reports from 2020-2023 showed that 26-43% of CBD products on the market have cannabinoid content inconsistent with the label. The European market is partially better regulated, but quality variability remains significant. Buy from trusted stores that publish COA for each batch.

Full-spectrum vs broad-spectrum vs isolate

• Full-spectrum: full spectrum of cannabinoids and terpenes, contains up to 0.3% THC; potentially "entourage effect," but may yield a positive result in a drug test.
• Broad-spectrum: spectrum of cannabinoids without THC; most commonly recommended for individuals sensitive to THC, athletes, professional drivers.
• Isolate: pure CBD (99%+), without cannabis taste and smell, without other cannabinoids; most predictable, least potential for synergy.

What to pay attention to when buying

Red flags of low quality: lack of COA on the site, "cures everything" in marketing, extremely low price (below 0.03 PLN per mg of CBD), lack of information about extraction (preferred CO2 supercritical) and origin of hemp (EU, organic), purchase at gas stations and vending machines.

Blind comparative trials by ConsumerLab (USA, 2022-2023) have repeatedly shown that products with extremely low prices had declared CBD content inflated by 40-80%. Quality comes at a cost, but overpaying does not guarantee effect.

Frequently Asked Questions (FAQ)

Can CBD be used every evening for a long time?

Long-term studies on CBD (Devinsky et al., Epilepsy, 2018, 48-week observation) show good tolerance without classical receptor tolerance. However, periodic monitoring of liver enzymes (ALT, AST) is recommended every 6-12 months at doses above 100 mg daily and therapeutic breaks every few months. The decision for chronic use should always be discussed with a doctor, especially in the presence of other diseases or medications.

How much CBD to take for sleep for the first time?

Clinical data from the Shannon 2019 study (The Permanente Journal) suggest starting with 25 mg sublingually 60-90 minutes before sleep for 14 days. If there is no effect, increase by 10-15 mg every 7 days, up to a maximum of 100 mg. Some individuals respond to 15 mg, while others need 50-75 mg. Keeping a sleep diary and objective assessment after 2-4 weeks, not after the first dose, is crucial.

Does CBD cause addiction?

According to the assessment of the WHO Expert Committee on Drug Dependence (2018), CBD does not exhibit addictive potential and does not cause classical withdrawal syndrome. Studies by Babalonis et al. (Drug and Alcohol Dependence, 2017) confirmed the absence of euphoric effect even at 800 mg. However, this does not mean that one cannot develop a psychological dependence on the evening ritual, so it is worth periodically verifying whether CBD still provides real benefits or has become a habit.

Can I combine CBD with melatonin?

Yes, combining CBD with 1-5 mg of melatonin is one of the more popular strategies, and in the study by Palmieri et al. (Medicines Basel, 2017) on 409 patients, good tolerance of such a combination was demonstrated. Melatonin targets the circadian rhythm, while CBD targets tension and anxiety. Start with lower doses of both, introduce them sequentially (first a week of just CBD, then add melatonin), and observe the reaction. With thyroid, autoimmune, and antidepressant medications, consult with a doctor before combining.

How long does CBD work for sleep?

Pharmacokinetics depend on the form: sublingual oil peaks after 30-90 minutes and works for 4-6 hours (Millar et al., Frontiers in Pharmacology, 2018); capsules and gummies peak in 2-3 hours and last 6-8 hours; vaporized flower acts within 5-10 minutes, but only for 2-3 hours. For individuals with nighttime awakenings, slower-releasing forms (capsules, gummies) may be better, while for falling asleep, sublingual oil.

Will CBD help if I can't sleep due to work stress?

Work stress often induces secondary insomnia due to excessive mental activation in the evening. CBD may help through an anxiolytic mechanism (5-HT1A, GABA), but only if you are simultaneously working on the cause. The supplement alone will not resolve chronic overwork. Consider: digital hygiene (ending work 2-3 hours before sleep), cognitive restructuring, online CBT-I, possibly psychological consultation. CBD is a piece of the puzzle, not the whole answer.

Can I drive after taking CBD in the evening?

In the study by Arkell et al. (CAVITY, 2020) 150 mg of CBD without THC did not significantly impair driving ability measured by a simulator test. However, in Poland, a THC concentration above 0.0 in the body is formally prohibited for drivers. Full-spectrum products with 0.3% THC could theoretically yield trace results in tests. For professional drivers, only isolate or certified broad-spectrum with confirmed 0 THC in COA are recommended, and caution should be exercised in the morning after an evening dose with unusual sedation.

Can CBD be used in children with sleep problems?

Definitely not, except for narrow medical indications (drug-resistant Dravet/Lennox-Gastaut epilepsy with a prescription for Epidiolex). The endocannabinoid system of a child develops until about the age of 25, and the long-term effects of CBD are not well studied. In children with sleep problems, the first step is pediatric assessment, exclusion of apnea (enlarged tonsils), assessment of sleep hygiene and circadian rhythm. Do not use CBD in children without a prescription.

Summary: does CBD improve sleep quality?

CBD may improve sleep quality in some individuals, especially those with insomnia related to anxiety, stress, or chronic pain. However, clinical evidence is preliminary: most studies are small trials, short observations, and lack hard polysomnographic measurements. The strongest data (Shannon 2019, The Permanente Journal, 66.7% improvement in 72 patients) pertains to insomnia secondary to anxiety.

Key principles of safe use: start with 15-25 mg of broad-spectrum oil 60-90 minutes before sleep, titrate every 7-14 days, keep a sleep diary, consult with a doctor when taking chronic medications (warfarin, SSRIs, statins, anticonvulsants), periodic monitoring of liver enzymes at doses above 100 mg. CBD will not replace CBT-I or diagnostics for the causes of insomnia.

If insomnia lasts more than 3 months, is accompanied by snoring with apneas, suicidal thoughts, excessive daytime sleepiness, night sweats, or weight loss, do not experiment with CBD, go to a doctor. Cannabidiol is a supportive tool, not a first-line therapy. In the hands of a conscious user and under the care of a specialist, it can be a reasonable part of a better sleep strategy.

The article written by Michał Waluk is educational and does not replace medical advice. In case of doubts, consult with a doctor or pharmacist. The information presented is based on scientific publications from PubMed, PMC databases, and AASM guidelines and Polish specialist societies.

Sources and further reading:

• Shannon S., Lewis N., Lee H., Hughes S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal, 23:18-041. PMC6326553
• Linares I.M.P., Guimaraes F.S., Eckeli A. et al. (2018). No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects. Frontiers in Pharmacology, 9:315.
• Babson K.A., Sottile J., Morabito D. (2017). Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Current Psychiatry Reports, 19(4):23.
• Kaul M., Zee P.C., Sahni A.S. (2021). Effects of Cannabinoids on Sleep and their Therapeutic Potential. Current Psychiatry Reports, 23:67.
• Chagas M.H.N., Eckeli A.L., Zuardi A.W. et al. (2014). Cannabidiol can improve complex sleep-related behaviours associated with RBD in Parkinson disease. J Clin Pharm Ther 39(5):564-566.
• Chesney E., Oliver D., Green A. et al. (2020). Adverse effects of cannabidiol: a systematic review. Neuropsychopharmacology 45:1799-1806.
• Brown J.D., Winterstein A.G. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer CBD Use. Journal of Clinical Medicine 8(7):989.
• Devinsky O., Patel A.D., Cross J.H. et al. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. NEJM 376:2011-2020.
• WHO Expert Committee on Drug Dependence (2018). Cannabidiol (CBD) Critical Review Report.
• Qaseem A., Kansagara D., Forciea M.A. et al. (2016). Management of Chronic Insomnia Disorder in Adults. Annals of Internal Medicine 165(2):125-133.